Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.

Takahashi S, Tateda K, Yanagihara K, Huang H, Doi Y, Yasuda M, Matsumoto K, Sumiya M, Takaya R, Suwada K, Kamiyabu S, Sasagawa Y, Minamida T, Kato S, Kondo K, Naruse T, Mikamo H

Open source

DOI
10.1016/s0140-6736(26)00596-9
Published
2026 May 16
Container
Lancet (London, England)
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-00596-9,
  title = {Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.},
  author = {Takahashi S and Tateda K and Yanagihara K and Huang H and Doi Y and Yasuda M and Matsumoto K and Sumiya M and Takaya R and Suwada K and Kamiyabu S and Sasagawa Y and Minamida T and Kato S and Kondo K and Naruse T and Mikamo H},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)00596-9},
  url = {https://doi.org/10.1016/s0140-6736(26)00596-9}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.
AU  - Takahashi S
AU  - Tateda K
AU  - Yanagihara K
AU  - Huang H
AU  - Doi Y
AU  - Yasuda M
AU  - Matsumoto K
AU  - Sumiya M
AU  - Takaya R
AU  - Suwada K
AU  - Kamiyabu S
AU  - Sasagawa Y
AU  - Minamida T
AU  - Kato S
AU  - Kondo K
AU  - Naruse T
AU  - Mikamo H
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)00596-9
UR  - https://doi.org/10.1016/s0140-6736(26)00596-9
ER  - 

APA

S, T., K, T., K, Y., H, H., Y, D., M, Y., K, M., M, S., R, T., K, S., S, K., Y, S., T, M., S, K., K, K., T, N., & H, M. (2026). Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)00596-9

Source records